The Recce (ASX:RCE) share price has surged up today. Here's why

The Recce Pharmaceuticals Ltd (ASX: RCE) share price is rocketing 6% higher today on gaining approval for clinical trials.

| More on:

Source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Recce Pharmaceuticals Ltd (ASX: RCE) share price is rocketing higher today following an update on its Recce 327 product.

In early trade, the medical company's share price hit an intra-day high of $1.19, but has since retreated to $1.12, up 6%.

What does Recce do?

Recce is involved in the advancement of synthetic antibodies designed to address the global health challenge of antibiotic resistance superbugs. The pharmaceutical company's flagship drug, Recce 327, is being developed to treat blood infections and sepsis.

The group operates solely in  research and development, and is located in both Australia and the United States.

Start of trials

Recce announced it had received an ethics approval to start clinical trials of its broad-spectrum antibiotic Recce 327 drug. The Human Research Ethics Committee (HREC) assessed the anti-viral formula and deemed it met ethical studies and guidelines.

Start of the phase I/II study will assess the efficacy of Recce 327 against infectious bacteria on burn wounds. The trial will involve up to 30 patients before expanding to a comparative effectiveness study based on the data. Over the 14 days, 10 patients will receive Recce 327 daily while a further 20 patients will receive treatment three times per week.

Once the trial period is completed, investigators will review the results and decide upon the best standards of care for future programs. In addition, burn wound specialists will oversee the delivery of Recce 327 via a spray-on-formulation.

The Health Department's South Metropolitan Health Service in Western Australia is expected to sponsor the trial. The Fiona Stanley Hospital (Burns Unit) in Perth is the nominated location.

Recce chair Dr John Prendergast  said:

Human ethics approval is another milestone for Recce and the clinicians seeking effective treatments to combat the scourge of antibiotic resistant bacteria. Achieving this goal speaks to the dedication of our clinical and research team as we continue to build on our clinical and commercial potential.

Should you invest?

I think that Recce has a promising future. If the company can deliver on its Recce 327 and Recce 529 compounds, then its share price could reach higher. It was only last month, the company updated the market on its fight against COVID-19.

At a market capitalisation of $194 million, the Recce share price has jumped 322% since this time last year. However, it is sitting almost 40% below its all-time high achieved in mid-September.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

a smiling young woman carrying a pile of books, indicating a lifting share price for book sellers
Share Market News

Here's how the ASX 200 market sectors stacked up last week

ASX utilities shares led the 11 market sectors for a second consecutive week.

Read more »

Animation of a man measuring a percentage sign, symbolising rising interest rates.
Share Market News

Here's when Westpac says the RBA will cut Australian interest rates

Are interest rates coming in 2024 or 2025?

Read more »

Contented looking man leans back in his chair at his desk and smiles.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A young boy sits on his father's shoulders as they flex their muscles at sunrise on a beach

Where I'd invest $10,000 in ASX growth shares right now

These are my top picks for growth.

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward representing the ASX tech share sell-off today
Share Market News

How likely is a stock market crash in 2024?

Stock market crashes are a painful, but inevitable, part of investing.

Read more »

a mine worker holds his phone in one hand and a tablet in the other as he stands in front of heavy machinery at a mine site.
Resources Shares

Goldman Sachs says this ASX 200 mining share is in for a 33% whack

The top broker predicts a fairly miserable 12 months ahead for this diversified miner.

Read more »

A woman wearing a top of gold coins and large gold hoop earrings and a heavy gold bracelet stands amid a shower of gold coins with her mouth open wide and an excited look on her face.

I believe this ASX 200 stock can DOUBLE its profit in 5 years

This stock has enormous profit growth potential in my eyes, here’s why.

Read more »

Top ten gold trophy.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors endured a sour end to the trading week today.

Read more »